Ferric Carboxymaltose (FCM)
Ferric Carboxymaltose (FCM) is a pharmaceutical drug with 18 clinical trials. Currently 1 active trials ongoing. Historical success rate of 100.0%.
Success Metrics
Based on 16 completed trials
Phase Distribution
Phase Distribution
0
Early Stage
5
Mid Stage
9
Late Stage
Highest Phase Reached
Phase 4Trial Status & Enrollment
100.0%
16 of 16 finished
0.0%
0 ended early
1
trials recruiting
18
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
Efficacy of Ferric Carboxymaltose Versus Iron Sucrose in Non-dialysis Dependent Chronic Kidney Disease Patients
The Role of Ferric Carboxymaltose in the Treatment of Pediatric Iron Deficiency Anemia in the Emergency Department
The Impact of IV Iron on Exercise Capacity and Quality of Life in Pulmonary Hypertension
Ferric Carboxymaltose Methemoglobinemia Study
Intravenous Iron Metabolism in Restless Legs Syndrome
Clinical Trials (18)
Efficacy of Ferric Carboxymaltose Versus Iron Sucrose in Non-dialysis Dependent Chronic Kidney Disease Patients
The Role of Ferric Carboxymaltose in the Treatment of Pediatric Iron Deficiency Anemia in the Emergency Department
The Impact of IV Iron on Exercise Capacity and Quality of Life in Pulmonary Hypertension
Ferric Carboxymaltose Methemoglobinemia Study
Intravenous Iron Metabolism in Restless Legs Syndrome
Evaluate the Outcomes of Ferric Carboxymaltose in Patients With Perioperative Anemia
A Study to Characterize the PK and PD Profile of IV FCM in Pediatric Subjects 1-17 Years Old With IDA
Use of Intravenous Ferric Carboxymaltose in Treatment of Anemia in Cancer Patients Undergoing Chemotherapy
Evaluation of Efficacy and Safety of Ferric Carboxymaltose (FCM) in Patients With Iron Deficiency Anemia and Impaired Renal Function
Safety and Efficacy of a Hematinic Agent in the Treatment of Postpartum Patients
Intravenous (IV) Iron Preparation (VIT-45) in the Treatment of Restless Legs Syndrome (RLS)
VIT45 Versus Oral Iron in the Treatment of Anemia in Non-Dialysis Dependent Chronic Kidney Disease
Comparison of the Safety and Efficacy of Intravenous Iron Versus Oral Iron in the Treatment of Anemia Secondary to Heavy Uterine Bleeding
Efficacy and Safety of Intravenous Ferric Carboxymaltose (FCM) in Patients With Iron Deficiency Anemia (IDA)
Long Term Safety Study of (VIT45) Extension Study: Treatment of Anemia in Non-Dialysis Dependent Chronic Kidney Disease
Safety and Tolerability of Ferric Carboxymaltose (FCM) Versus Standard of Care in Treating Iron Deficiency Anemia
Hypophosphatemia With Ferric Carboxymaltose Vs. Iron Dextran in Iron Deficiency Secondary to Heavy Uterine Bleeding
Intravenous Ferric Carboxymaltose vs IV Iron Sucrose or IV Iron Dextran in Treating Iron Deficiency Anemia in Women
All 18 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 18